Palisade Bio, Inc. (PALI)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
PALI Insider Trading Activity
PALI Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $9,673 | 2 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Williams Donald Allen | director | 1 | $4,863 | 0 | $0 | $4,863 |
| Finley John David | CEO, CFO, Director | 1 | $4,810 | 0 | $0 | $4,810 |
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. …
Insider Activity of Palisade Bio, Inc.
Over the last 12 months, insiders at Palisade Bio, Inc. have bought $9,673 and sold $0 worth of Palisade Bio, Inc. stock.
On average, over the past 5 years, insiders at Palisade Bio, Inc. have bought $46,086 and sold $192 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Williams Donald Allen (director) — $4,863. Finley John David (CEO, CFO, Director) — $4,810.
The last purchase of 1,000 shares for transaction amount of $4,863 was made by Williams Donald Allen (director) on 2024‑05‑28.
List of Insider Buy and Sell Transactions, Palisade Bio, Inc.
| 2024-05-28 | Williams Donald Allen | director | 1,000 0.1091% | $4.86 | $4,863 | -28.36% | ||
| 2024-05-24 | Finley John David | CEO, CFO, Director | 1,000 0.0994% | $4.81 | $4,810 | -30.55% | ||
| 2024-02-06 | Finley John David | CEO, CFO, Director | 10,000 0.0819% | $0.47 | $4,692 | -43.76% | ||
| 2024-01-31 | Finley John David | CEO, CFO, Director | 10,000 0.0976% | $0.56 | $5,590 | -56.28% | ||
| 2024-01-31 | Williams Donald Allen | director | 10,000 0.1056% | $0.60 | $6,050 | -56.28% | ||
| 2023-09-27 | Finley John David | CEO, CFO, Director | 15,000 0.1655% | $0.54 | $8,088 | -24.34% | ||
| 2023-09-27 | Williams Donald Allen | director | 20,000 0.221% | $0.54 | $10,800 | -24.34% | ||
| 2023-09-14 | Sale | Trenschel Robert J. | director | 300 0.0034% | $0.64 | $192 | -33.15% | |
| 2023-09-13 | Finley John David | CEO, CFO, Director | 15,000 0.2077% | $0.66 | $9,825 | -35.85% | ||
| 2022-09-01 | Finley John David | Chief Financial Officer | 19,481.24 0.0402% | $0.14 | $2,799 | -69.79% | ||
| 2022-08-23 | Finley John David | Chief Financial Officer | 7,350 0.0144% | $0.16 | $1,176 | -73.51% | ||
| 2022-03-29 | Dawson Michael John | Chief Medical Officer | 15,000 0.0958% | $1.14 | $17,093 | -89.84% | ||
| 2022-03-28 | Hallam Thomas | Chief Executive Officer | 10,000 0.0655% | $1.18 | $11,800 | -89.81% | ||
| 2022-03-24 | Finley John David | Chief Financial Officer | 7,500 0.045% | $1.09 | $8,174 | -89.78% | ||
| 2021-09-21 | Finley John David | Chief Financial Officer | 2,000 0.0164% | $2.44 | $4,880 | -62.00% | ||
| 2021-09-21 | Hallam Thomas | Chief Executive Officer | 6,000 0.0502% | $2.49 | $14,940 | -62.00% | ||
| 2021-09-10 | Trenschel Robert J. | director | 2,142 0.0176% | $2.98 | $6,383 | -67.75% | ||
| 2021-09-09 | Trenschel Robert J. | director | 3,400 0.028% | $2.89 | $9,826 | -66.59% | ||
| 2021-09-08 | Trenschel Robert J. | director | 5,000 0.0424% | $2.75 | $13,750 | -63.62% | ||
| 2021-09-07 | Trenschel Robert J. | director | 2,707 0.0215% | $2.78 | $7,525 | -66.09% |
Insider Historical Profitability
| Finley John David | CEO, CFO, Director | 8437 0.305% | $7,740.95 | 10 | 0 | <0.0001% |
| Williams Donald Allen | director | 1000 0.0362% | $917.50 | 3 | 0 | <0.0001% |
| GARR RICHARD | CEO | 240000 8.6769% | $220,200.00 | 2 | 3 | |
| OLDAKER WILLIAM CLYDE | director | 116939 4.2278% | $107,291.53 | 7 | 0 | |
| CONRON JOHN | Chief Financial Officer | 51364 1.857% | $47,126.47 | 3 | 0 |
Historical Insider Profitability vs. Competitors
$1,138,733 | 28 | -4.94% | $2.7M | |
$63,749,694 | 24 | -12.24% | $2.37M | |
$193,112 | 22 | -20.59% | $1.52M | |
$1,616,354 | 20 | -12.22% | $3.22M | |
$613,181 | 18 | -20.90% | $2.12M |
PALI Institutional Investors: Active Positions
| Increased Positions | 6 | +100% | 145,458 | +234.24% |
| Decreased Positions | 2 | -33.33% | 8,333 | -13.42% |
| New Positions | 2 | New | 80,058 | New |
| Sold Out Positions | <1 | Sold Out | 8,200 | Sold Out |
| Total Postitions | 10 | +66.67% | 199,223 | +220.82% |
PALI Ownership Change vs Market
Institutional Investor Ownership
| Armistice Capital, Llc | $87.00 | 3.51% | 105,367 | +53,367 | +102.63% | 2024-12-31 |
| Cetera Investment Advisers | $58.00 | 2.33% | 70,006 | +70,006 | New | 2024-12-31 |
| Geode Capital Management, Llc | $8.00 | 0.34% | 10,052 | +10,052 | New | 2024-12-31 |
| Ubs Group Ag | $7.00 | 0.3% | 8,974 | +8,943 | +28,848.39% | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $4.00 | 0.16% | 4,686 | +3,089 | +193.43% | 2024-12-31 |
| Federation Des Caisses Desjardins Du Quebec | $0 | <0.01% | 100 | 0 | 0% | 2024-12-31 |
| Wells Fargo & Company/Mn | $0 | <0.01% | 21 | 0 | 0% | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | 0% | 10 | +<1 | +11.11% | 2024-12-31 |
| Morgan Stanley | $0 | 0% | 7 | -133 | -95% | 2024-12-31 |
| Jpmorgan Chase & Co | $0 | 0% | 0 | -8,200 | Sold Out | 2024-12-31 |